Tech Company Financing Transactions
Orionis Biosciences Funding Round
Orionis Biosciences closed a $55 million investment round on 10/19/2022. Investors included Cormorant Asset Management, Novartis and private investors.
Transaction Overview
Company Name
Announced On
10/19/2022
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Undisclosed
Investors
Cormorant Asset Management (Lead Investor)
Novartis (Lead Investor)
Proceeds Purpose
The company intends to use the funds for R&D expansion, pipeline growth and advancement of its lead cancer immunotherapy programs into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
950 Winter St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
A fully integrated spectrum of expertise for rational drug discovery. We are an early stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical need -- with an initial internal focus in oncology and immunotherapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nikolai Kley
Chief Scientific Officer
Riccardo Sabatini
Chief Technical Officer
Jan Tavernier
Vice President
Edward Suh
VP - Finance
Andrew Littlehale
VP - Operations
James Kyranos
Browse more venture capital transactions:
Prev: 10/19/2022: Shardeum venture capital transaction
Next: 10/19/2022: Upheal venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs